Potential Cure For Arthritis In First Human Trial

The idea of a revolutionary ‘wonder drug’ is something we are usually sceptical about. After all, isn’t it too much to hope for a drug that can cure a condition in just a single dose? It now seems that this idea is not as fantastic as we thought, with the advent of the first human trial of a potential ‘cure’ for rheumatoid arthritis.

A single dose of a new drug could completely reform the immune system of sufferers of rheumatoid arthritis, according to researchers who are about to embark on the first human trial of the project. Scientists from King’s College London, Guy’s and St Thomas’ NHS Foundation Trusts are due to start the first human trial of binding immunoglobulin protein (BiP). BiP was developed in the lab in an attempt to recreate one of the body’s own natural proteins, which acts as an anti-inflammatory. Sufferers of rheumatoid arthritis have a deficiency of this particular protein; so a replenishing dose should, theoretically, bring their immune system back to a state of full functioning.

Up to 50 participants, all sufferers of rheumatoid arthritis, will be given an intravenous dose of BiP in an attempt to imitate the body’s own natural anti-inflammatory response. The research team are confident that the trial will build further hope in the possibility of using the treatment on a widespread scale, after previously gaining positive results in animal trials. Their greatest hope is that just a single injection will provide long-lasting relief from rheumatoid arthritis, and represent a complete rejuvenation of the immune system.

Around 400,000 adults suffer from rheumatoid arthritis in the UK. The condition has a strong adverse effect on their day-to-day wellbeing, causing pain in the joints and decreased mobility. It is estimated that 1,000 people have to give up work every year due to the extent of their suffering. If BiP works as expected, these patients will be able to hope for an immediate remission of the disease. Not only will they benefit from a restored sense of wellness, but the healthcare hours saved by the NHS will be considerable. After 15 years in the making, the results of BiP’s first human trial are keeping us all in hopeful expectation.

 

Comments are closed.